• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗儿童肺动脉高压的枸橼酸西地那非临时口服混悬剂。

Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children.

作者信息

Nahata Milap C, Morosco Richard S, Brady Michael T

机构信息

The Ohio State University, Columbus, OH 43210, USA.

出版信息

Am J Health Syst Pharm. 2006 Feb 1;63(3):254-7. doi: 10.2146/ajhp050208.

DOI:10.2146/ajhp050208
PMID:16434784
Abstract

PURPOSE

The stability of sildenafil citrate 2.5 mg/mL in two extemporaneously prepared oral suspensions stored at 4 and 25 degrees C was studied.

METHODS

Thirty 25-mg tablets of sildenafil citrate were ground to powder, and the powder was combined with a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of methylcellulose 1% and Simple Syrup, NF, to produce two 2.5-mg/mL suspensions. Five plastic bottles of each suspension were stored in amber plastic prescription bottles at 4 or 25 degrees C. Samples were collected on days 0, 7, 14, 28, 42, 56, 70, and 91 for analysis of sildenafil content by high-performance liquid chromatography; pH was also measured. Samples were visually observed against black and white backgrounds.

RESULTS

The mean concentration of sildenafil citrate exceeded 98% of the initial concentration in all samples at both temperatures throughout the 91-day study period. No changes in pH, odor, or physical appearance were observed.

CONCLUSION

Sildenafil citrate 2.5 mg/mL in two extemporaneously compounded oral suspensions was stable for 91 days in plastic prescription bottles at 4 and 25 degrees C.

摘要

目的

研究枸橼酸西地那非2.5毫克/毫升在两种临时配制的口服混悬液中于4℃和25℃储存时的稳定性。

方法

将30片25毫克的枸橼酸西地那非片剂研磨成粉末,然后将该粉末与Ora - Sweet和Ora - Plus的1:1混合物或1%甲基纤维素与NF级单糖浆的1:1混合物混合,制成两种2.5毫克/毫升的混悬液。每种混悬液的五个塑料瓶分别储存在琥珀色塑料处方瓶中,于4℃或25℃保存。在第0、7、14、28、42、56、70和91天采集样品,用高效液相色谱法分析西地那非含量;同时测量pH值。样品分别在黑色和白色背景下进行目视观察。

结果

在整个91天的研究期间,两种温度下所有样品中枸橼酸西地那非的平均浓度均超过初始浓度的98%。未观察到pH值、气味或外观的变化。

结论

两种临时配制的含2.5毫克/毫升枸橼酸西地那非的口服混悬液在塑料处方瓶中于4℃和25℃下91天内稳定。

相似文献

1
Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children.用于治疗儿童肺动脉高压的枸橼酸西地那非临时口服混悬剂。
Am J Health Syst Pharm. 2006 Feb 1;63(3):254-7. doi: 10.2146/ajhp050208.
2
Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4 and 25 degrees C.
Am J Health Syst Pharm. 1999 Feb 1;56(3):240-2. doi: 10.1093/ajhp/56.3.240.
3
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children.吗啡和西地那非口服制剂在婴幼儿中的稳定性延长
Int J Pharm Compd. 2016 May-Jun;20(3):247-249.
4
Stability of propylthiouracil in extemporaneously prepared oral suspensions at 4 and 25 degrees C.丙硫氧嘧啶在4℃和25℃下临时配制的口服混悬液中的稳定性。
Am J Health Syst Pharm. 2000 Jun 15;57(12):1141-3.
5
Stability of extemporaneously prepared moxifloxacin oral suspensions.莫西沙星口服混悬液的临时配制稳定性。
Am J Health Syst Pharm. 2009 Apr 1;66(7):665-7. doi: 10.2146/ajhp080152.
6
Stability of extemporaneously prepared glycopyrrolate oral suspensions.临时制备的格隆溴铵口服混悬液的稳定性。
Am J Health Syst Pharm. 2011 May 1;68(9):843-5. doi: 10.2146/100247.
7
Stability of an extemporaneous alcohol-free melatonin suspension.无醇褪黑素混悬液的稳定性。
Am J Health Syst Pharm. 2011 Mar 1;68(5):420-3. doi: 10.2146/ajhp100274.
8
Stability of extemporaneously prepared rifaximin oral suspensions.利福昔明口服混悬剂的稳定性。
Am J Health Syst Pharm. 2010 Feb 15;67(4):287-9. doi: 10.2146/ajhp090206.
9
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children.
Int J Pharm Compd. 2016 May-Jun;20(3):257-261.
10
Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions.临时配制的苯丁酸钠口服混悬液的稳定性。
Am J Health Syst Pharm. 2007 Jul 15;64(14):1513-5. doi: 10.2146/ajhp060450.

引用本文的文献

1
Paediatric medicine issues and gaps from healthcare workers point of view: survey results and a narrative review from the global accelerator for paediatric formulations project.从医护人员角度看儿科医学问题与差距:全球儿科制剂项目加速器的调查结果及叙述性综述
Front Pharmacol. 2023 Jul 17;14:1200848. doi: 10.3389/fphar.2023.1200848. eCollection 2023.
2
Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience.关于用于婴幼儿肺动脉高压的他达拉非混悬液制剂的多中心回顾:北美经验
Front Pediatr. 2023 Jan 26;11:1055131. doi: 10.3389/fped.2023.1055131. eCollection 2023.
3
Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension.
单剂量西地那非口服给药在慢性栓塞性肺动脉高压犬模型中的药代动力学
J Vet Med Sci. 2020 Apr 9;82(4):446-451. doi: 10.1292/jvms.19-0595. Epub 2020 Feb 26.
4
Drug Treatment of Pulmonary Hypertension in Children.儿童肺动脉高压的药物治疗。
Paediatr Drugs. 2020 Apr;22(2):123-147. doi: 10.1007/s40272-019-00374-2.
5
Compounding and stability evaluation of atorvastatin extemporaneous oral suspension using tablets or pure powder.使用片剂或纯粉末对阿托伐他汀临时口服混悬液进行配制及稳定性评估。
Eur J Hosp Pharm. 2017 May;24(3):157-161. doi: 10.1136/ejhpharm-2016-000913. Epub 2016 Jun 15.
6
Physicochemical and Microbiological Stability of the Extemporaneous Sildenafil Citrate Oral Suspension.枸橼酸西地那非临时口服混悬液的物理化学和微生物稳定性
Sci Pharm. 2015 Jul 7;83(4):659-70. doi: 10.3797/scipharm.1505-08. Print 2015 Oct-Dec.
7
Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports.先天性心脏病患儿舌下含服西地那非后生物利用度大幅提高:两例病例报告。
J Med Case Rep. 2014 May 30;8:171. doi: 10.1186/1752-1947-8-171.
8
Drug treatment of pulmonary hypertension in children.儿童肺动脉高压的药物治疗。
Paediatr Drugs. 2014 Feb;16(1):43-65. doi: 10.1007/s40272-013-0052-2.
9
Sildenafil for the treatment of pulmonary hypertension in pediatric patients.西地那非用于治疗儿科患者的肺动脉高压。
Pediatr Cardiol. 2009 Oct;30(7):871-82. doi: 10.1007/s00246-009-9523-1. Epub 2009 Aug 25.
10
Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.为监测英国儿童药品可及性建立基线:1998 - 2002年
Br J Clin Pharmacol. 2007 Jan;63(1):85-91. doi: 10.1111/j.1365-2125.2006.02729.x. Epub 2006 Jul 26.